Gamco Investors INC. ET AL decreased its position in shares of BioTelemetry Inc (NASDAQ:BEAT) by 57.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,652 shares of the medical research company’s stock after selling 11,900 shares during the period. Gamco Investors INC. ET AL’s holdings in BioTelemetry were worth $517,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of BEAT. BlackRock Inc. boosted its position in shares of BioTelemetry by 7.8% during the 3rd quarter. BlackRock Inc. now owns 4,957,817 shares of the medical research company’s stock worth $319,531,000 after acquiring an additional 360,529 shares in the last quarter. Loomis Sayles & Co. L P acquired a new stake in shares of BioTelemetry during the 3rd quarter worth approximately $23,211,000. Fuller & Thaler Asset Management Inc. acquired a new stake in shares of BioTelemetry during the 3rd quarter worth approximately $9,947,000. Credit Suisse AG boosted its position in shares of BioTelemetry by 18.2% during the 3rd quarter. Credit Suisse AG now owns 826,222 shares of the medical research company’s stock worth $53,250,000 after acquiring an additional 127,195 shares in the last quarter. Finally, Point72 Asset Management L.P. boosted its position in shares of BioTelemetry by 332.4% during the 3rd quarter. Point72 Asset Management L.P. now owns 92,100 shares of the medical research company’s stock worth $5,936,000 after acquiring an additional 70,800 shares in the last quarter. Institutional investors and hedge funds own 88.27% of the company’s stock.

In other BioTelemetry news, VP Heather C. Getz sold 93,383 shares of the firm’s stock in a transaction that occurred on Tuesday, January 29th. The shares were sold at an average price of $70.06, for a total value of $6,542,412.98. Following the sale, the vice president now owns 119,085 shares in the company, valued at $8,343,095.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Heather C. Getz sold 8,236 shares of the firm’s stock in a transaction that occurred on Thursday, January 17th. The shares were sold at an average price of $70.01, for a total transaction of $576,602.36. Following the completion of the sale, the vice president now owns 88,797 shares in the company, valued at approximately $6,216,677.97. The disclosure for this sale can be found here. Insiders sold 177,198 shares of company stock worth $12,419,736 in the last 90 days. Company insiders own 8.30% of the company’s stock.

Shares of BioTelemetry stock opened at $73.98 on Friday. BioTelemetry Inc has a fifty-two week low of $29.85 and a fifty-two week high of $80.92. The company has a current ratio of 2.68, a quick ratio of 2.50 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $2.45 billion, a price-to-earnings ratio of 43.25, a P/E/G ratio of 4.13 and a beta of 1.75.

BEAT has been the topic of several analyst reports. Raymond James reduced their price target on shares of BioTelemetry from $66.00 to $64.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 31st. BidaskClub upgraded shares of BioTelemetry from a “buy” rating to a “strong-buy” rating in a research report on Friday, January 11th. Zacks Investment Research upgraded shares of BioTelemetry from a “hold” rating to a “buy” rating and set a $86.00 price target on the stock in a research report on Tuesday. Sidoti set a $95.00 price target on shares of BioTelemetry and gave the stock a “buy” rating in a research report on Tuesday. Finally, ValuEngine upgraded shares of BioTelemetry from a “buy” rating to a “strong-buy” rating in a research report on Monday, February 4th. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $71.00.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2019/02/09/gamco-investors-inc-et-al-has-517000-position-in-biotelemetry-inc-beat.html.

About BioTelemetry

BioTelemetry, Inc, a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology.

Recommended Story: What is a bull market?

Want to see what other hedge funds are holding BEAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioTelemetry Inc (NASDAQ:BEAT).

Institutional Ownership by Quarter for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.